Molecular basis of hypertension side effects induced by sunitinib

Area of Science:

• Oncology
• Cardiovascular Research
• Pharmacology

Background:

• Vascular complications, including hypertension, are increasingly observed in patients receiving novel cancer therapies.
• Hypertension is a common adverse effect of angiogenesis inhibitors, particularly small-molecule inhibitors targeting vascular endothelial growth factor (VEGF) signaling.
• The precise mechanisms driving therapy-induced hypertension are not fully understood but involve endothelial dysfunction and angiogenesis abnormalities.

Purpose of the Study:

• To investigate the vascular complications, with a specific focus on hypertension, associated with tyrosine kinase inhibitor (TKI) treatment.
• To explore the potential mechanisms by which TKIs induce hypertension, including effects on the microvasculature.

Main Methods:

• The study examines vascular complications in patients treated with the TKI sunitinib (SU11248).
• Analysis focuses on changes in microvascular networks, endothelial function, and nitric oxide metabolism.

Main Results:

• Treatment with TKIs, such as sunitinib, is linked to significant and sustained increases in blood pressure.
• Hypertensive patients exhibit reduced arterioles and capillaries, altered microvascular networks, decreased vascular compliance, and reduced nitric oxide bioactivity.
• Elevated plasma vascular endothelial growth factor levels are observed in hypertensive patients.

Conclusions:

• TKIs may directly impact the microvasculature, leading to hypertension through mechanisms like vascular rarefaction and endothelial dysfunction.
• Understanding these vascular effects is crucial for managing cancer patients undergoing TKI therapy.